After finishing at $3.04 in the prior trading day, Clover Health Investments Corp (NASDAQ: CLOV) closed at $3.0, down -1.15%. In other words, the price has decreased by -$1.15 from its previous closing price. On the day, 7.77 million shares were traded. CLOV stock price reached its highest trading level at $3.05 during the session, while it also had its lowest trading level at $2.91.
Ratios:
Our goal is to gain a better understanding of CLOV by taking a closer look at its different ratios. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on December 17, 2024, initiated with a Buy rating and assigned the stock a target price of $6.
On October 07, 2024, UBS started tracking the stock assigning a Neutral rating and target price of $4.
Cowen Upgraded its Underperform to Market Perform on February 02, 2022, whereas the target price for the stock was revised from $7 to $3.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 22 ’25 when Wai Conrad sold 118,600 shares for $3.29 per share. The transaction valued at 390,194 led to the insider holds 1,494,898 shares of the business.
Wai Conrad sold 91,197 shares of CLOV for $302,774 on Jul 23 ’25. The CEO, Counterpart Health now owns 1,403,701 shares after completing the transaction at $3.32 per share. On Jul 03 ’25, another insider, Reynoso Jamie L., who serves as the CEO, Medicare Advantage of the company, sold 19,789 shares for $2.58 each. As a result, the insider received 51,056 and left with 3,308,539 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLOV now has a Market Capitalization of 1526750976 and an Enterprise Value of 1384466816. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.03 while its Price-to-Book (P/B) ratio in mrq is 4.29. Its current Enterprise Value per Revenue stands at 0.931 whereas that against EBITDA is -60.441.
Stock Price History:
The Beta on a monthly basis for CLOV is 1.93, which has changed by 0.5625 over the last 52 weeks, in comparison to a change of 0.17535925 over the same period for the S&P500. Over the past 52 weeks, CLOV has reached a high of $4.87, while it has fallen to a 52-week low of $1.50. The 50-Day Moving Average of the stock is -1.51%, while the 200-Day Moving Average is calculated to be -15.75%.
Shares Statistics:
The stock has traded on average 8.51M shares per day over the past 3-months and 9447120 shares per day over the last 10 days, according to various share statistics. A total of 388.51M shares are outstanding, with a floating share count of 382.35M. Insiders hold about 24.87% of the company’s shares, while institutions hold 21.07% stake in the company. Shares short for CLOV as of 1752537600 were 36198932 with a Short Ratio of 4.25, compared to 1749772800 on 22280296. Therefore, it implies a Short% of Shares Outstanding of 36198932 and a Short% of Float of 8.930001.
